期刊
CHEMICAL REVIEWS
卷 121, 期 4, 页码 2545-2647出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.chemrev.0c01122
关键词
-
资金
- PAIP [5000-9155, LANCAD-UNAM-DGTIC-306]
- CONACyT Ciencia Basica [A1-S-8866]
- National Science Foundation [CHE-1900416]
- National Institutes of Health [R01 GM107703]
- European Research Council (ERC), Consolidator Grant (CoG) BioDisOrder [819644]
- Cheney Visiting Scholar Fellowship from the University of Leeds
- NSF Division of Chemical, Bioengineering, Environmental, and Transport Systems [1743432, 1512059]
- ERC [258748]
- National Cancer Institute, National Institutes of Health [HHSN26120080001E]
- Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research
- Helmholtz ERC Recognition Award
- NSF [1806138, 1825122]
- European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie [840395]
- National Institutes for Health [1R35 GM134864, UL1 TR002014]
- Passan Foundation
- Extreme Science and Engineering Discovery Environment (XSEDE) through the National Science Foundation (NSF) [TG-MCA05S027]
- National Science Foundation (NSF) [MCB-1716956]
- National Institutes of Health (NIH) [RF1AG044342, R21-AG065693, R01-NS092918, R01-AG062135, R56-NS113549, R01-GM118560-01A]
- National Science Foundation MRSEC [DMR 1720256]
- Center for Scientific Computing at the California Nanosystems Institute (NSF) [CNS1725797]
- University of Minnesota Foundation
- National Key Research and Development Program of China [2016YFA0501702]
- Universite de Paris, ANR SIMI7 [GRAL 12-BS07-0017]
- Initiative d'Excellence program from the French State [ANR-11-LABX0011-01]
- CNRS Institute of Chemistry (INC)
- ERC (FP7/2007-2013) [258748]
- Institute of Translational Neuroscience
- Directorate For Engineering
- Div Of Chem, Bioeng, Env, & Transp Sys [1743432, 1512059] Funding Source: National Science Foundation
- Marie Curie Actions (MSCA) [840395] Funding Source: Marie Curie Actions (MSCA)
- European Research Council (ERC) [819644, 258748] Funding Source: European Research Council (ERC)
Protein misfolding and aggregation are common in amyloidogenic diseases, and understanding how amyloid species become toxic is crucial for treatment development. Experiments using computer modeling, in vitro and in vivo studies, as well as pharmacology, have provided valuable insights into the accumulation and deposition of amyloid species, contributing to research on diseases like Alzheimer's, Parkinson's, diabetes, and ALS.
Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting either the central nervous system or a variety of peripheral tissues. Structural and dynamic characterization of all species along the pathways from monomers to fibrils is challenging by experimental and computational means because they involve intrinsically disordered proteins in most diseases. Yet understanding how amyloid species become toxic is the challenge in developing a treatment for these diseases. Here we review what computer, in vitro, in vivo, and pharmacological experiments tell us about the accumulation and deposition of the oligomers of the (A beta, tau), alpha-synuclein, IAPP, and superoxide dismutase 1 proteins, which have been the mainstream concept underlying Alzheimer's disease (AD), Parkinson's disease (PD), type II diabetes (T2D), and amyotrophic lateral sclerosis (ALS) research, respectively, for many years.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据